Oral Care Brand Bitvae Receives American Dental Association Certificate for its D2 and S2 Smart Electric Toothbrushes
The brand's connected technology and intuitive product features help its users monitor and improve their oral care routine and that of their families. NEW YORK, Nov. 22, 2022 /PRNewswire/ -- Bitvae, a brand dedicated to making its customers' oral care routine easy and enjoyable with high-performance products, is pleased to announce that it has received the American Dental Association (ADA)...
Luvme Cares for Women’s Health in Alopecia & Breast Cancer Themed Charity Events
NEW YORK, Nov. 22, 2022 /PRNewswire/ -- Luvme Hair, a leading brand in the wig industry in North America, invited her customers to participate in a series of events across her social media communities to raise awareness for alopecia, illness-induced hair loss, and breast cancer. Enlightened and inspired by the customers' true and spirit-lifting stories, the brand donated $5,000 to...
Interplex Announces Stackable Multi-Row Board-to-Board Connector Products That Achieve Unprecedented Flexibility
Automotive-grade product offers a reliable, repeatable and versatile solution that can be scaled up in line with specific customer requirements SINGAPORE, Nov. 22, 2022 /PRNewswire/ -- Interplex, a world leader in designing and manufacturing interconnect and mechanical products, is successfully addressing the growing market demand for high-density interconnects in challenging application scenarios. The company has just released its Multi-Row Board-to-Board...
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an important development in radioisotope production. High activity generators from...
PUBLICATION OF THE OFFERING CIRCULAR IN RELATION TO THE MERGER BETWEEN DSM and Firmenich and the LISTING OF DSM-Firmenich ON EURONEXT AMSTERDAM
THIS PRESS RELEASE IS NOT FOR GENERAL RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO, DIRECTLY OR INDIRECTLY, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS This is a joint press release by Koninklijke DSM N.V. (DSM),...
3Z: Zebrafish mutant model reveals novel drug candidates for ADHD
REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the development of non-stimulant based therapeutics is of high importance. In a study published in the journal Neuropsychopharmacology, 3Z...
FWD Group focuses on wellness for season three of its popular podcast series “Celebrate Living with FWD”
Season three airs today and brings together leading experts to explore all aspects of wellness: from mental and physical health through to financial wellness, social connectivity, purpose and meaning in life Seasons one and two established a global audience spanning 50 countries HONG KONG, Nov. 22, 2022 /PRNewswire/ -- FWD Group Holdings Limited ("FWD Group")...
Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology
SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at the 45th San Antonio Breast Cancer Symposium (SABCS 2022) from 6-10 December 2022. Breast cancer is the most common malignant cancer...
First Patient Dosed in Phase II ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy
MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM). TLX101 (4-L- iodo-phenylalanine,...
Quantivly exhibits at RSNA 2022 with AI-driven software to transform the way radiology leaders manage operations and increase access to imaging for the population.
Company's vision is to develop a "digital twin" for radiology facilities to allow monitoring, simulation, and optimization of operations with software before implementation in the real world. SOMERVILLE, Mass., Nov. 21, 2022 /PRNewswire/ -- Quantivly is highlighting new advances in its artificial intelligence (AI)-driven software for improving efficiency in medical imaging at the Radiological Society of North America (RSNA)...
